Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

For patients with optimally treated chronic myeloid leukemia (CML), discontinuation of tyrosine kinase inhibitor (TKI) therapy can lead to treatment-free remission. In previous trials, TKI discontinuation has been associated with increased musculoskeletal pain in some patients (“withdrawal syndrome...

Full description

Bibliographic Details
Main Authors: Kathryn E. Flynn, Ehab Atallah, Li Lin, Neil P. Shah, Richard T. Silver, Richard A. Larson, Javier Panilla-Ibarz, James E. Thompson, Vivian G. Oehler, Jerald P. Radich, Vamsi Kota, Michael J. Mauro, Charles A. Schiffer, Jorge Cortes, Kevin P. Weinfurt
Format: Article
Language:English
Published: Ferrata Storti Foundation 2022-05-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/10635

Internet

https://haematologica.org/article/view/10635

Similar Items